&w=3840&q=100)
UK unemployment rises to nearly three-year high at 4.6%, wage growth slows too
The rise in joblessness levels came as the UK's Labour government began implementing a business tax increase announced in its first budget last October read more
Britain's unemployment rate rose to its highest level in nearly three years, official figures showed Tuesday (June 10), as businesses faced mounting pressure from higher taxes and new trade tariffs imposed by the United States.
The Office for National Statistics said the jobless rate increased to 4.6 per cent in the three months to the end of April, up from 4.5 per cent in the first quarter. It marked the highest reading since July 2021.
STORY CONTINUES BELOW THIS AD
The rise came as the UK's Labour government began implementing a business tax increase announced in its first budget last October. At the same time, a 10 per cent baseline tariff imposed on British goods by US President Donald Trump took effect in April, hitting exporters and manufacturers.
'There continues to be weakening in the labour market, with the number of people on payroll falling notably,' said Liz McKeown, ONS director of economic statistics. 'Feedback from our vacancies survey suggests some firms may be holding back from recruiting new workers or replacing people when they move on.'
Wage growth also showed signs of slowing, contributing to expectations that the Bank of England will continue cutting interest rates to support the economy.
The central bank lowered its key interest rate by a quarter percentage point to 4.25% in May. Some analysts now expect further reductions into next year.
'With payrolls falling, the unemployment rate climbing and wage growth easing, today's labour market release leaves us more confident in our view that the Bank of England will cut interest rates further than investors expect, to 3.50 per cent next year,' said Ruth Gregory, deputy chief UK economist at Capital Economics.
STORY CONTINUES BELOW THIS AD
The pound edged lower on the news, while London's FTSE 100 stock index rose in early trading as markets priced in a more dovish outlook from the central bank.
With inputs from AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
38 minutes ago
- Mint
Trump wants cheaper drugs like Europe has. How it works.
President Donald Trump doesn't just want to bring down prescription drug prices for Americans. He wants European countries to raise them to make up the revenue that drugmakers would lose from his policy. Trump is proposing a so-called most-favored-nation pricing model, which would set U.S. drug prices at the lowest level in other wealthy countries. But the pharmaceutical industry isn't buying into tying drug prices in the U.S. to prices in Europe—at least not knowing the details of the president's proposal. More details about the government's pricing model could come this week. On May 12, Trump directed government health officials to benchmark drug prices to international standards within 30 days. The lobbying group PhRMA, with members including U.S. pharma giants Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie, has argued there are two reasons why U.S. drug prices are high: foreign countries not paying 'their fair share" for medicines, and middlemen such as pharmacy-benefit managers. Today, U.S. drug pricing is largely market driven. It involves negotiations between drug manufacturers, pharmacy-benefit managers, healthcare insurers and providers. European countries do it much differently. Each has its own way of determining drug prices, but most follow one of two broad approaches. The first approach, which Germany and France use, considers the overall clinical effectiveness of a new medicine. How does the new treatment compare to existing ones? Does it have added therapeutic benefits? If the new drug is substantially better, its price would reflect that. A second approach, used by the U.K., the Netherlands, and Sweden, analyzes cost effectiveness. This model not only compares the new drug to existing ones but also assesses the incremental value that the medicine brings to the health system. After the assessments, negotiations between drugmakers and the countries begin. Because many European countries have national health systems, they are in a strong negotiation position. If government negotiators think a medicine is too expensive for its effectiveness, they won't recommend its use. How Trump's MFN policy would work in practice isn't clear. Drug prices would probably be based on list prices in Europe since the prices paid by national health systems, or net prices, are confidential. The president's open-ended directive, laid out in an executive order, has many wondering how the U.S. could raise prices in Europe. Trump has made clear he wants to close the gap between U.S. and international prices, and has suggested he would use tariffs and export controls to achieve his goal. In theory, drugmakers could set list prices higher in Europe as long as it doesn't affect net prices, health policy expert Dr. Huseyin Naci told Barron's. In the U.K., for example, a higher list price could still lower the prices in other European countries. 'So that would still not be an acceptable approach to many other European countries," said Naci, who is associate professor of health policy at the London School of Economics. Overhauling Europe's decades-old pricing approaches would require fundamental changes to their pricing regulations—and there will be 'little appetite or ability" to alter them, Naci added. Cost is another complicating factor. 'Pharmaceutical spending is already one of the top categories of spending in many countries in terms of healthcare expenditure, so there's little room to accommodate higher prices and spending for pharmaceuticals in Europe," according to Naci. How Trump is planning to make Europeans pay more for drugs is the big question. He could use tariffs and trade negotiations as leverage. In early April, the president said a 'major" tax on pharmaceutical imports is coming 'very shortly," however nothing has been announced yet. In a trade agreement with the U.K. a month later, there is a provision on pharmaceuticals that states the U.K. will 'endeavor to improve the overall environment for pharmaceutical companies." What that means in practice still isn't clear. Write to Elsa Ohlen at
Business Standard
40 minutes ago
- Business Standard
Rupee extends further gains as dollar deepens losses
The Indian rupee extended further gains on Thursday tracking deep losses in the dollar overseas following softer than expected US inflation report that could support case for a Federal rate cut. Dollar index moved below 98 mark as investors now await US PPI data for more clarity. Moreover, US President Donald Trump has reignited tariff threats by announcing plans to notify US trading partners within the next one to two weeks about the new unilateral tariff rates. Rupee opened at Rs 85.43 per dollar but eased to a low of 85.49 so far during the day. Yesterday, INR appreciated 6 paise to close at 85.51 against the US dollar. Indian shares eked out modest gains on Wednesday. The benchmark 30-share BSE Sensex edged up by 123.42 points, or 0.15 percent, to 82,515.14 while the broader NSE Nifty index closed up 37.15 points, or 0.15 percent, at 25,141.40. On the NSE, USDINR futures were down marginally at 85.52.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Block deals, IPOs surge as investors race to tap India's booming market
The South Asian nation saw $6.4 billion raised through share sales in May, the highest monthly total since December 2024, according to data compiled by Bloomberg Bloomberg India's market for share sales is warming up after a several dull months, as companies and shareholders cash in on a buoyant stock market. The South Asian nation saw $6.4 billion raised through share sales in May, the highest monthly total since December 2024, according to data compiled by Bloomberg. Block trades worth $5 billion were the biggest contributors, marking the busiest month for such deals since March last year. The momentum has carried into June, with at least 10 blocks raising $1.2 billion in the first week alone. Indian stocks are now positioned for more gains after the central bank on Friday delivered a bigger-than-expected interest rate cut and injected further liquidity into the banking system. This has supported a rally that's already underway, with the benchmark NSE Nifty 50 Index rebounding from its April lows, which were triggered by concerns over US President Donald Trump's broad tariffs. 'Right now, investors are saying, 'I need exposure to India — and I need it fast,'' said Sunil Khaitan, a managing director leading financing in India at Goldman Sachs Group Inc. 'Block trades remain the quickest and most efficient way to get that exposure.' The recent torrent of deals stands in contrast to the lull earlier in 2025, when local deals cooled off after a record-breaking year. India even ceded its position to Hong Kong as the world's second-largest market for share sales in the first three months of the year, weighed down by an unexpected slowdown in economic growth and cautious corporate earnings forecasts. Some of the largest recent block trades include British American Tobacco Plc's $1.5 billion sale of tobacco manufacturer ITC Ltd.'s shares, Singapore Telecommunications Ltd.'s $1.5 billion selldown of wireless carrier Bharti Airtel Ltd.'s stock and billionaire Rakesh Gangwal's $1.4 billion disposal of shares in IndiGo's parent company. Private equity firm Carlyle Group and South Korean automaker Hyundai Motor Co. were also among those paring their India holdings. The flurry of activity with blocks appears to be spilling over to IPOs. HDB Financial Services Ltd. recently secured a nod from the securities regulator for a first-time sale that could raise $1.5 billion. Prudential Plc's Indian asset management venture is also nearing a filing for a listing expected to fetch as much as $1.2 billion, according to people familiar with the matter. Better-than-expected corporate earnings and decent economic growth provide a robust backdrop for deals, which could include billion-dollar IPOs later this year, said Samarth Jagnani, Morgan Stanley's head of global capital markets for India and Southeast Asia. 'The second half will be better,' he said. Despite the recovery, Indian deals remain well below last year's $66 billion record. Total share sales — including IPOs, placements and blocks — have raised $15.5 billion so far this year, 29% lower from the year-ago period, according to Bloomberg-compiled data. Some IPOs are also moving ahead with tamer valuations: Solar-pump maker Oswal Pumps Ltd. this week said its IPO was looking to raise Rs 13.9 billion ($162 million), lower than what it targeted last year.
